Neuren Pharmaceuticals (ASX: NEU)Share Price and News
About Neuren Pharmaceuticals
Neuren Pharmaceuticals is an Australian biopharmaceutical company specialising in developing therapies for serious neurodevelopmental disorders that manifest in early childhood.
Neuren's flagship product, DAYBUE™ (trofinetide), is a synthetic analogue of the neuropeptide IGF-1 and has been approved by the U.S FDA for Rett Syndrome.
Rett syndrome is a rare brain disorder that leads to severe impediments, such as a loss of motor skills and language. Rett syndrome becomes apparent after 6-18 months of age and almost exclusively impacts females. There are currently no other FDA-approved medicines for this disease.
The company's current goals are expanding its share in the US and to to expand the use of trofinetide in other jurisdictions and for other indications. The company is also advancing other assets at the R&D phase.
Neuren's Company History
Neuren Pharmaceuticals was founded in 2001 and initially focused on developing Glypromate to prevent cognitive impairment after cardiac surgery. However, after the Phase 3 trial of Glypromate failed in 2008, the company strategically pivoted to concentrate on neurodevelopmental disorders, leading to the development of trofinetide.
In 2018, Neuren signed a deal with San Diego-based company Acadia Pharmaceuticals, giving Arcadia the North American rights to Trofinetide in the event of commercialisation. In return, Acadia agreed to fund a phase III trial for Rett Syndrome and commercialisation costs if and when it entered the market.
The Arcadia-funded Phase III trial was a complete success, meeting the primary endpoints on a statistically significant basis. After the trial was concluded in late 2021, Neuren and Acadia made their case to the FDA and the green light was given in March 2023.
Trofinetide thus became the only approved treatment for Rett Syndrome. It also gave Neuren a Rare Pediatric Disease Priority Review Voucher (PRV) as well as US$40m a month later when the first sale was made, along with royalties on net sales and one third of the market value of the PRV.
In CY23, Daybue made US$177.2m in sales, and followed this up with US$348.4m in CY24 and $391m in CY25, over $900m all up. This led to almost A$150m in royalties (A$27m in CY23, A$56.2m in CY24 and $65m in CY25) to Neuren along with in milestone and upfront payments, plus A$76.5m from Neuren’s one third of net proceeds from the sale of its PRV.
Neuren's Future Outlook
The outlook for Neuren Pharmaceuticals is largely driven by the commercial success of its Rett syndrome drug trofinetide and the development progress of its next-generation compound NNZ-2591. Trofinetide, marketed as DAYBUE, is the first and currently only approved therapy for Rett syndrome in the United States, giving the drug a strong competitive position in a rare disease market with few alternative treatments. Neuren does not directly market the drug in the United States, instead receiving royalty payments from its commercial partner Acadia Pharmaceuticals based on global sales.
Since its launch in 2023, sales of DAYBUE have grown steadily as clinicians adopt the treatment for eligible patients. The drug addresses a population of several thousand patients in the United States alone, and because rare disease therapies typically command very high pricing, the commercial opportunity is significant even with relatively small patient numbers. Neuren benefits from this model because royalties and milestone payments can generate strong margins without requiring the company to build a large global sales organisation.
A key catalyst for the company’s near-term outlook is geographic expansion. Regulators in Europe have been reviewing trofinetide for potential approval, which could significantly increase the drug’s addressable market. Under its agreement with Acadia, Neuren may receive substantial milestone payments and tiered royalties on European sales if regulatory approvals are granted and commercialisation proceeds.
In addition to geographic expansion, the therapy itself continues to evolve. In late 2025 the FDA approved a new powder formulation known as DAYBUE STIX, designed to make the medication easier to administer and improve dosing flexibility for patients. The new formulation is expected to launch commercially in 2026 and could help broaden adoption among patients and caregivers.
Beyond trofinetide, the most important driver of future value is the development of NNZ-2591. This compound is currently undergoing clinical trials for several rare neurological disorders, including Angelman syndrome, Pitt Hopkins syndrome and Phelan-McDermid syndrome. Positive clinical results could significantly expand Neuren’s potential revenue base because each of these conditions represents a new therapeutic market with limited existing treatments.
Looking ahead to FY26, Neuren has told investors to expect >$70m in royalties. Its outlook centres on continued growth in sales from trofinetide, potential regulatory approvals in additional markets and further clinical progress from NNZ-2591 trials. These developments could determine whether the company transitions from a single-product biotech into a broader neurodevelopmental therapy platform.
Is Neuren a Good Stock to Buy?
Whether Neuren Pharmaceuticals represents an attractive investment largely depends on an investor’s tolerance for biotechnology risk and their view of the long-term potential of the company’s drug pipeline. Biotech stocks are inherently volatile because company valuations are closely tied to regulatory approvals and clinical trial outcomes. However, Neuren is somewhat less speculative than many early-stage biotechnology companies because it already has an FDA-approved drug generating commercial revenue through royalties.
One of the most appealing aspects of Neuren’s business model is its partnership structure. By licensing trofinetide to Acadia Pharmaceuticals in North America, Neuren avoided the substantial cost of running large-scale clinical trials and building a global marketing operation. Instead, the company earns royalties on net sales as well as milestone payments tied to regulatory approvals and commercial performance. This model allows the company to maintain relatively low operating costs while still benefiting from global drug sales growth.
Financially, the commercialisation of DAYBUE has already begun to translate into profitability. Royalty income from the drug has supported rising earnings and cash flow, with Neuren reporting growing profit in recent financial periods as adoption of the therapy increased. This shift from a cash-burning research company to a profitable biotechnology business is a significant milestone for investors assessing the stock.
However, the investment case also carries important risks. The company remains heavily reliant on a single commercial product, meaning any slowdown in DAYBUE adoption or competitive therapies could affect revenue growth. In addition, the value of Neuren’s pipeline depends heavily on the success of clinical trials for NNZ-2591 and other compounds, which inherently carry scientific and regulatory uncertainty.
Ultimately, Neuren is often viewed as a growth-oriented biotechnology stock with asymmetric upside potential. If DAYBUE continues to expand globally and additional drugs from the pipeline achieve regulatory approval, the company could develop into a leading specialist in treatments for rare neurological disorders. On the other hand, as with many biotech investments, the stock can experience large price swings depending on trial results, regulatory decisions and commercial uptake of its therapies.
Our Stock Analysis
Here are 5 ASX Biotech Targets Amidst The $230bn Patent Cliff; And Which Big Pharma Companies Could Buy Them!
There are plenty of ASX Biotech Targets that major pharmaceutical companies wanting to minimise the impact of the Patent Cliff…
Neuren (ASX:NEU) Crashes 10% on EU Setback: Is This a Buying Opportunity?
Neuren Pharmaceuticals: Is the 10% drop a buy signal? Neuren Pharmaceuticals (ASX: NEU) dropped nearly 10% on Tuesday, falling to…
Neuren Pharmaceuticals (ASX:NEU) Surges 6% on US$700m DAYBUE Target: Time to Buy?
DAYBUE royalties could climb fast if US targets land Neuren Pharmaceuticals (ASX: NEU) jumped 6% on Wednesday after its US…
Neuren Pharmaceuticals (ASX:NEU) Gets FDA Approval- Is It a Buy?
Neuren Pharmaceuticals (ASX: NEU) rose 2.5% yesterday after the US FDA approved DAYBUE STIX, a new powder formulation of its…
There’s a US$180bn Biotech Patent Cliff coming! Here’s why it could spell doom for large caps, but a generational opportunity for small caps
There’s a Biotech Patent Cliff coming over the next decade! Investors aren’t giving this much attention, but we think they…
ASX Health Care Stocks Under Trump: Who’ll Win and Who’ll Lose?
What does the next few years hold for ASX Health Care Stocks Under Trump? There’s no doubt that the health…
Frequently Asked Questions
Neuren develops therapies for serious neurodevelopmental disorders, including Rett syndrome, Phelan-McDermid, Angelman, Pitt-Hopkins, and Prader-Willi syndromes. Its flagship asset Trofinetide is FDA-approved in the USA for Rett Syndrome.